Last updated: June 1, 2026
GOLYTELY (polyethylene glycol 3350 + electrolytes) suppliers: manufacturers, contract suppliers, and sourcing risks
GOLYTELY is supplied in the US as a prescription bowel-prep product. The supplier landscape is centered on the branded manufacturer’s own supply chain and any contract manufacturing organizations (CMOs) used for drug substance, drug product, packaging, and labeling. This analysis maps the procurement touchpoints typically implicated for GOLYTELY and the specific sourcing risks that show up in bowel-prep supply.
Who manufactures GOLYTELY in the US?
The branded GOLYTELY product is manufactured and supplied under the label of the US marketing authorization holder on the FDA label and current distribution network. In practice, procurement teams source through:
- The label holder’s direct supply arrangements
- Wholesaler distribution for secondary-market procurement
- Specialty distributors for hospital and GI endoscopy channels
- CMOs for finished-dose granulation, blending, sachet/bottle filling, and packaging
Because bowel-prep products are sensitive to batch consistency (osmotic strength, electrolyte ratios, particle size distribution, and water-soluble excipients), the supplier roster tends to be stable with occasional switches during facility downtime or capacity ramps.
What parts of GOLYTELY supply typically come from different vendors?
- Drug product manufacturing: blending and filling of PEG + electrolytes into the marketed dosage form (typically large-volume sachet/bottle presentations).
- Packaging and secondary packaging: bottles, cartons, labeling, and lot-coded distribution packaging for GI channel usage.
- Quality systems: testing for electrolyte composition, PEG molecular weight distribution, uniformity, and stability.
- Raw materials:
- PEG 3350 and electrolyte salts (sodium, chloride, bicarbonate sources, potassium source)
- Microcrystalline or other excipient inputs depending on the exact formulation variant
- Flavoring and color components, if present in the marketed presentation
Which raw material suppliers support GOLYTELY sourcing?
Bowel-prep inputs are usually procured as commodity-to-specialty chemicals with controlled specifications. In GOLYTELY, the bottlenecks that affect supply are typically:
- PEG 3350 supply continuity (commodity chemical sourcing, molecular weight range controls)
- Electrolyte salt availability and lot-to-lot specification control (particle size, assay, hydration state)
- Packaging components (bottle caps, closures, sachet film/laminates, carton materials) when packaging plants have constraints
For procurement risk planning, the actionable focus is less on “who sells PEG” in the abstract and more on whether the label holder and CMOs qualify alternate lots quickly under GMP change control.
How do contract manufacturers (CMOs) for GOLYTELY usually factor into supply?
For products like GOLYTELY, CMOs typically operate in one of two models:
- Full-service CMO: blending, filling, and packaging under the label holder’s QMS and CoA release framework.
- Packaging-only or bottling-only CMO: drug product manufactured in-house or at another site, then packaged and labeled under contract.
Procurement teams should treat CMO involvement as a batch-traceability and lead-time variable. When a CMO changes or a packaging line switches, the supply disruption risk increases even if “drug substance” remains unchanged.
What is the fastest way to identify the real GOLYTELY supplier chain?
The supplier chain is evidenced in three places used by procurement and quality teams:
- US FDA label “Manufactured for” / “Distributed by” statements on the current carton labeling (primary source of label-holder and manufacturer-of-record).
- NDC-specific product listings used by wholesalers and hospitals to confirm which physical SKU is in channel.
- Regulatory filings and inspection history (site identifiers that show which facility is actively manufacturing the marketed dosage form).
What Orange Book status does GOLYTELY have, and does it list suppliers?
GOLYTELY is a classic bowel-prep drug with active ingredients widely used across generic products. Orange Book status, if present for specific strengths/forms, typically lists patents and exclusivity rather than supplier names. The Orange Book does not function as a supplier directory. For supplier identification, the FDA label and listing details tied to the NDC are the practical sources.
Which generic or AB-rated equivalents compete with GOLYTELY and how does that affect suppliers?
Bowel-prep products share similar “electrolyte + PEG” mechanisms across brands and generics. When competitors enter, procurement dynamics can change:
- Multiple finished-dose manufacturers expand capacity for the same active ingredient combination.
- Wholesalers may dual-source under different NDCs depending on allocation and supply constraints.
- Hospital formularies may pivot between equivalent presentations, shifting volume to whichever site is producing reliably.
When does GOLYTELY face supply constraints, and what supplier levers reduce risk?
Bowel-prep supply constraints are usually capacity- or QA-driven:
- Raw material lot failures or specification excursions (PEG or electrolyte salts)
- Line stoppages in filling/packaging
- Labeling or packaging component shortages
- Hold/release delays due to sterility is not relevant here, but chemical and content-uniformity testing is
Supplier-risk mitigation levers:
- Qualify alternate NDCs and presentations if label-equivalent
- Maintain buffer inventory for endoscopy scheduling windows
- Pre-negotiate distributor allocation terms
- Use lot-level traceability to track underlying manufacturing site changes
What manufacturing/IP barriers influence supplier switching for GOLYTELY?
For a PEG-electrolyte bowel-prep product, the switching barriers are usually not patent-driven, but operational:
- Formulation and process controls under GMP
- Established analytical methods and acceptance criteria
- Stability qualification for the packaged dosage form
- Validation of blending, dissolution/osmotic behavior, and electrolyte ratios
- Packaging component compatibility and shelf-life
What procurement documents matter for GOLYTELY supplier qualification?
For regulated buyers, supplier qualification is anchored on:
- Certificate of Analysis (CoA) per lot and full specification sheet
- Master Production Record controls for mixing/blending steps
- Change control history tied to manufacturing site or packaging line
- Stability protocol and actual ongoing stability data
- Labeling reconciliation and NDC traceability
Key supplier mapping table for GOLYTELY sourcing execution
The table below shows the supplier-chain nodes procurement teams should map from label and NDC-specific records.
| Supplier-chain node |
What to confirm |
Why it matters for GOLYTELY procurement |
| Manufacturer-of-record (drug product) |
“Manufactured for/by” on label; site name and address |
Determines GMP site, batch release chain, and capacity |
| Label holder / marketing authorization entity |
“Distributed by” on label |
Controls supply allocation and recalls |
| CMO role (if applicable) |
Evidence in label or packaging label copy |
Switches lead time and quality release behavior |
| Drug product packaging |
Bottle/sachet filling site and label printer |
Drives line constraints and lot-to-lot labeling variation |
| PEG 3350 supply |
Qualified raw material source and specs |
PEG MW distribution impacts dissolution and performance |
| Electrolyte salts supply |
Salt source, hydration state control, particle size |
Impacts electrolyte ratios and uniformity |
| Quality control testing |
Release testing labs and methods |
Affects release timelines and hold/release cycles |
Key takeaways
- GOLYTELY’s supplier chain is best understood as a label-holder driven system with GMP manufacturing at one (or a small number of) defined sites, possibly supported by CMOs for blending/filling/packaging.
- Procurement risk concentrates in PEG 3350 and electrolyte salt lot control, plus packaging-line availability and QA release testing capacity.
- Supplier identification for contracting or due diligence should be built from label “manufactured for/distributed by” statements and NDC-specific product records, not from Orange Book patent listings.
FAQs
1) Does GOLYTELY have multiple NDCs that reflect different manufacturing sites?
Procurement should verify lot-coded manufacturing site through NDC-specific product labeling and lot traceability records.
2) Are PEG 3350 and electrolyte salts interchangeable across GOLYTELY suppliers?
Interchangeability depends on qualified specifications for molecular weight range and electrolyte composition; raw material substitution triggers change control under GMP.
3) How can procurement teams detect a manufacturing site change for GOLYTELY?
Monitor lot numbers, CoA manufacturing site fields, and label “manufactured for/by” copy for the specific NDC and presentation.
4) Do generic PEG-electrolyte bowel preps reduce supply risk for GOLYTELY?
They can, because wholesalers and institutions may allocate by AB-equivalency across brands, shifting volume to better-capacity producers.
5) What are the most common causes of bowel-prep shortages impacting GOLYTELY?
Raw material spec failures, packaging component constraints, line stoppages, and QA release delays.
References
- US Food and Drug Administration. GOLYTELY (polyethylene glycol 3350 and electrolytes) prescribing information and FDA label. FDA access data.
- US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA access data.
